Company intelligence / Profile preview

Lumos Diagnostics

Sarasota, Florida, United Stateslumosdiagnostics.com ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Lumos Diagnostics has commercialized rapid point-of-care diagnostic tests such as FebriDx and ViraDx. FebriDx aids in differentiating bacterial from non-bacterial acute respiratory infections using a fingerstick blood sample. ViraDx detects COVID‑19 and influenza A/B simultaneously. The company has achieved Medicare reimbursement for FebriDx in the US and continues to expand clinical validation studies

Therapeutic areas: ImmunologyInfectious Diseases
Modalities: Device
Industry: Protein Biomarker Diagnostics

Partnerships

Hologic (major development and IP agreements signed in January 2024)Custom assay/reader development partnerships with various healthcare companies/clients.

Beyond the preview

Go deeper on Lumos Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lumos Diagnostics.

Explore the full profile